{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:26:15Z","timestamp":1792110375112,"version":"4.4.0"},"reference-count":121,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Multiple sclerosis (MS) causes sensory and motor deficiencies by breaking the myelin\nsheath, which inhibits electrical impulses from reaching affected neurons. The blood-brain barrier\n(BBB) and unanticipated side effects from inadequate targeting are major hurdles to MS treatment.\nNanomedicines are being used to deliver therapeutic chemicals to lesions in order to address the\nlimitations of existing MS therapy approaches. Nano-based therapies with deep BBB penetration and\nselective targeting have shown promising results, emerging as a possible therapy strategy for MS\nwith improved therapeutic effects. This review will suggest the latest developments in nano-colloidsbased\ntherapy for treating MS by evaluating their advantages and disadvantages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115672018330624241125060045","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:21:09Z","timestamp":1750396869000},"page":"338-350","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brain Targeting Using Nanocolloids for the Management of Multiple Sclerosis"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-5792","authenticated-orcid":true,"given":"Smita","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Central University of Rajasthan, Bandarsindri, Distt. Ajmer, Rajasthan 305817, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisar","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Central University of Rajasthan, Bandarsindri, Distt. Ajmer, Rajasthan 305817, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1","volume":"23","year":"1954","unstructured":"ALLISON RS.; MILLAR, JH. Prevalence of disseminated sclerosis in northern Ireland. Ulster Med J  1954,23(Suppl. 2),1-27","journal-title":"Ulster Med J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","author":"Wallin M.T.","year":"2019","unstructured":"Wallin M.T.; Culpepper W.J.; Nichols E.; Bhutta Z.A.; Gebrehiwot T.T.; Hay S.I.; Khalil I.A.; Krohn K.J.; Liang X.; Naghavi M.; Mokdad A.H.; Nixon M.R.; Reiner R.C.; Sartorius B.; Smith M.; Topor-Madry R.; Werdecker A.; Vos T.; Feigin V.L.; Murray C.J.L.; Global, regional, and national burden of multiple sclerosis 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol  2019,18(3),269-285","journal-title":"Lancet Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1212\/NXI.0000000000000713","volume":"7","author":"Willumsen J.S.","year":"2020","unstructured":"Willumsen J.S.; Aarseth J.H.; Myhr K.M.; Midgard R.; High incidence and prevalence of MS in M\u00f8re and Romsdal County, Norway, 1950-2018. Neurol Neuroimmunol Neuroinflammation,  2020,7,e713","journal-title":"Neurol Neuroimmunol Neuroinflammation,"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/brainsci10050305","volume":"10","author":"Boyko A.","year":"2020","unstructured":"Boyko A.; Melnikov M.; Prevalence and incidence of multiple sclerosis in Russian federation: 30 years of studies. Brain Sci  2020,10(5),305","journal-title":"Brain Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","volume":"31","author":"Oh J.","year":"2018","unstructured":"Oh J.; Vidal-Jordana A.; Montalban X.; Multiple sclerosis: Clinical aspects. Curr Opin Neurol  2018,31(6),752-759","journal-title":"Curr Opin Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"Dobson R.","year":"2019","unstructured":"Dobson R.; Giovannoni G.; Multiple sclerosis - A review. Eur J Neurol  2019,26(1),27-40","journal-title":"Eur J Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.autrev.2020.102512","volume":"19","author":"Inojosa H.","year":"2020","unstructured":"Inojosa H.; Schriefer D.; Ziemssen T.; Clinical outcome measures in multiple sclerosis: A review. Autoimmun Rev  2020,19(5),102512","journal-title":"Autoimmun Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","volume":"263","author":"Ziemssen T.","year":"2016","unstructured":"Ziemssen T.; Derfuss T.; de Stefano N.; Giovannoni G.; Palavra F.; Tomic D.; Vollmer T.; Schippling S.; Optimizing treatment success in multiple sclerosis. J Neurol  2016,263(6),1053-1065","journal-title":"J Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2055217320901727","DOI":"10.1177\/2055217320901727","volume":"6","author":"Nicholas R.S.","year":"2020","unstructured":"Nicholas R.S.; Heaven M.L.; Middleton R.M.; Chevli M.; Pulikottil-Jacob R.; Jones K.H.; Ford D.V.; Personal and societal costs of multiple sclerosis in the UK: A population-based MS registry study. Mult Scler J Exp Transl Clin  2020,6(1),2055217320901727","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/WCO.0000000000000811","volume":"33","author":"Sorensen P.S.","year":"2020","unstructured":"Sorensen P.S.; Fox R.J.; Comi G.; The window of opportunity for treatment of progressive multiple sclerosis. Curr Opin Neurol  2020,33(3),262-270","journal-title":"Curr Opin Neurol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1021\/acs.molpharmaceut.1c00892","volume":"19","author":"Jan Z.","year":"2022","unstructured":"Jan Z.; Mollazadeh S.; Abnous K.; Taghdisi S.M.; Danesh A.; Ramezani M.; Alibolandi M.; Targeted delivery platforms for the treatment of multiple Sclerosis. Mol Pharm  2022,19(7),1952-1976","journal-title":"Mol Pharm"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0022-510X(09)70003-6","volume":"277","author":"Murray T.J.","year":"2009","unstructured":"Murray T.J.; The history of multiple sclerosis: The changing frame of the disease over the centuries. J Neurol Sci  2009,277(Suppl. 1),S3-S8","journal-title":"J Neurol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1212\/CON.0000000000000725","volume":"25","author":"Nourbakhsh B.","year":"2019","unstructured":"Nourbakhsh B.; Mowry E.M.; Multiple sclerosis risk factors and pathogenesis. Continuum (Minneap Minn)  2019,25(3),596-610","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/ijms20020303","volume":"20","author":"Tarlinton R.E.","year":"2019","unstructured":"Tarlinton R.E.; Khaibullin T.; Granatov E.; Martynova E.; Rizvanov A.; Khaiboullina S.; The interaction between viral and environmental risk factors in the pathogenesis of multiple sclerosis. Int J Mol Sci  2019,20(2),303","journal-title":"Int J Mol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/00207454.2019.1677648","volume":"130","author":"Tobore T.O.","year":"2020","unstructured":"Tobore T.O.; Towards a comprehensive etiopathogenetic and pathophysiological theory of multiple sclerosis. Int J Neurosci  2020,130(3),279-300","journal-title":"Int J Neurosci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/1352458519898332","volume":"Apr; 26","author":"Patsopoulos N.A.","year":"2020","unstructured":"Patsopoulos N.A.; De Jager P.L.; Genetic and gene expression signatures in multiple sclerosis. Mult Scler  2020,Apr; 26(5),576-581","journal-title":"Mult Scler"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00044-023-03170-3\/FIGURES\/10","author":"Jain S.","year":"2023","unstructured":"Jain S.; Sharma S.; Paliwal A.; Dwivedi J.; Paliwal S.; Paliwal V.; Paliwal S.; Sharma J.; Discovery of novel fatty acid amide hydrolase (FAAH) inhibitors as anti-alzheimer\u2019s agents through pharmacophore-based virtual screening, molecular docking and experimental validation. Med Chem Res  2023,1-15","journal-title":"Med Chem Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/jnr.24596","volume":"99","author":"Lioudyno V.","year":"2021","unstructured":"Lioudyno V.; Abdurasulova I.; Negoreeva I.; Stoliarov I.; Kudriavtsev I.; Serebryakova M.; Klimenko V.; Lioudyno M.; A common genetic variant rs2821557 in KCNA3 is linked to the severity of multiple sclerosis. J Neurosci Res  2021,99(1),200-208","journal-title":"J Neurosci Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","volume":"8","author":"Lassmann H.","year":"2018","unstructured":"Lassmann H.; Multiple sclerosis pathology. Cold Spring Harb Perspect Med  2018,8(3),a028936","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"Trapp B.D.","year":"2008","unstructured":"Trapp B.D.; Nave K.A.; Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci  2008,31(1),247-269","journal-title":"Annu Rev Neurosci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00702-013-1080-3","volume":"120","author":"Chaudhuri A.","year":"2013","unstructured":"Chaudhuri A.; Multiple sclerosis is primarily a neurodegenerative disease. J Neural Transm (Vienna)  2013,120(10),1463-1466","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1093\/brain\/awz201","volume":"142","author":"Wentling M.","year":"2019","unstructured":"Wentling M.; Lopez-Gomez C.; Park H.J.; Amatruda M.; Ntranos A.; Aramini J.; Petracca M.; Rusielewicz T.; Chen E.; Tolstikov V.; Kiebish M.; Fossati V.; Inglese M.; Quinzii C.M.; Katz Sand I.; Casaccia P.; A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis. Brain  2019,142(9),2756-2774","journal-title":"Brain"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3389\/fimmu.2019.02403","volume":"10","author":"Moreira A.","year":"2019","unstructured":"Moreira A.; Alari-Pahissa E.; Munteis E.; Vera A.; Zabalza A.; Llop M.; Villarrubia N.; Costa-Garc\u00eda M.; \u00c1lvarez-Lafuente R.; Villar L.M.; L\u00f3pez-Botet M.; Mart\u00ednez-Rodr\u00edguez J.E.; Adaptive features of natural killer cells in multiple sclerosis. Front Immunol  2019,10,2403","journal-title":"Front Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","volume":"64","author":"Bar-Or A.","year":"2007","unstructured":"Bar-Or A.; Vollmer T.; Antel J.; Arnold D.L.; Bodner C.A.; Campagnolo D.; Gianettoni J.; Jalili F.; Kachuck N.; Lapierre Y.; Niino M.; Oger J.; Price M.; Rhodes S.; Robinson W.H.; Shi F.D.; Utz P.J.; Valone F.; Weiner L.; Steinman L.; Garren H.; Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1\/2 trial. Arch Neurol  2007,64(10),1407-1415","journal-title":"Arch Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/acn3.783","volume":"6","author":"Konjevic Sabolek M.","year":"2019","unstructured":"Konjevic Sabolek M.; Held K.; Beltr\u00e1n E.; Niedl A.G.; Meinl E.; Hohlfeld R.; Lassmann H.; Dornmair K.; Communication of CD8+ T cells with mononuclear phagocytes in multiple sclerosis. Ann Clin Transl Neurol  2019,6(7),1151-1164","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","volume":"3","author":"Gajofatto A.","year":"2015","unstructured":"Gajofatto A.; Benedetti M.D.; Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases  2015,3(7),545-555","journal-title":"World J Clin Cases"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nurt.2007.07.008","volume":"4","author":"Frohman E.M.","year":"2007","unstructured":"Frohman E.M.; Shah A.; Eggenberger E.; Metz L.; Zivadinov R.; St\u00fcve O.; Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics  2007,4(4),618-626","journal-title":"Neurotherapeutics"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biomedicines7030056","volume":"7","author":"Macaron G.","year":"2019","unstructured":"Macaron G.; Ontaneda D.; Diagnosis and management of progressive multiple sclerosis. Biomedicines  2019,7(3),56","journal-title":"Biomedicines"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"Scolding N.","year":"2015","unstructured":"Scolding N.; Barnes D.; Cader S.; Chataway J.; Chaudhuri A.; Coles A.; Giovannoni G.; Miller D.; Rashid W.; Schmierer K.; Shehu A.; Silber E.; Young C.; Zajicek J.; Association of British Neurologists: Revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol  2015,15(4),273-279","journal-title":"Pract Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","volume":"32","author":"Cree B.A.C.","year":"2019","unstructured":"Cree B.A.C.; Mares J.; Hartung H.P.; Current therapeutic landscape in multiple sclerosis: An evolving treatment paradigm. Curr Opin Neurol  2019,32(3),365-377","journal-title":"Curr Opin Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-019-0969-0","volume":"20","author":"Di Stefano G.","year":"2019","unstructured":"Di Stefano G.; Maarbjerg S.; Truini A.; Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain  2019,20(1),20","journal-title":"J Headache Pain"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acn3.84","volume":"1","author":"Kasper L.H.","year":"2014","unstructured":"Kasper L.H.; Reder A.T.; Immunomodulatory activity of interferon-beta. Ann Clin Transl Neurol  2014,1(8),622-631","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"Jacobs L.D.","year":"1996","unstructured":"Jacobs L.D.; Cookfair D.L.; Rudick R.A.; Herndon R.M.; Richert J.R.; Salazar A.M.; Fischer J.S.; Goodkin D.E.; Granger C.V.; Simon J.H.; Alam J.J.; Bartoszak D.M.; Bourdette D.N.; Braiman J.; Brownscheidle C.M.; Coats M.E.; Cohan S.L.; Dougherty D.S.; Kinkel R.P.; Mass M.K.; Munschauer F.E.; Priore R.L.; Pullicino P.M.; Scherokman B.J.; Whitham R.H.; Whitham R.H.; Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol  1996,39(3),285-294","journal-title":"Ann Neurol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2147\/PPA.S68698","volume":"8","author":"Caporro M.","year":"2014","unstructured":"Caporro M.; Disanto G.; Gobbi C.; Zecca C.; Two decades of subcutaneous glatiramer acetate injection: Current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient Prefer Adherence  2014,8,1123-1134","journal-title":"Patient Prefer Adherence"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/sj.leu.2402887","volume":"17","author":"Cattaneo C.","year":"2003","unstructured":"Cattaneo C.; Almici C.; Borlenghi E.; Motta M.; Rossi G.; A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia  2003,17(5),985-986","journal-title":"Leukemia"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1586\/14737175.2014.915742","volume":"14","author":"Cocco E.","year":"2014","unstructured":"Cocco E.; Marrosu M.G.; The current role of mitoxantrone in the treatment of multiple sclerosis. Expert Rev Neurother  2014,14(6),607-616","journal-title":"Expert Rev Neurother"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"549842","DOI":"10.3389\/fimmu.2020.549842","volume":"11","author":"Khoy K.","year":"2020","unstructured":"Khoy K.; Mariotte D.; Defer G.; Petit G.; Toutirais O.; Le Mauff B.; Natalizumab in multiple sclerosis treatment: From biological effects to immune monitoring. Front Immunol  2020,11,549842","journal-title":"Front Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"Brinkmann V.","year":"2010","unstructured":"Brinkmann V.; Billich A.; Baumruker T.; Heining P.; Schmouder R.; Francis G.; Aradhye S.; Burtin P.; Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov  2010,9(11),883-897","journal-title":"Nat Rev Drug Discov"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrneurol.2010.76","volume":"6","author":"Aktas O.","year":"2010","unstructured":"Aktas O.; K\u00fcry P.; Kieseier B.; Hartung H.P.; Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol  2010,6(7),373-382","journal-title":"Nat Rev Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","volume":"74","author":"Bar-Or A.","year":"2014","unstructured":"Bar-Or A.; Pachner A.; Menguy-Vacheron F.; Kaplan J.; Wiendl H.; Teriflunomide and its mechanism of action in multiple sclerosis. Drugs  2014,74(6),659-674","journal-title":"Drugs"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.clinthera.2015.08.003","volume":"37","author":"Miller A.E.","year":"2015","unstructured":"Miller A.E.; Teriflunomide: A once-daily oral medication for the treatment of relapsing forms of multiple sclerosis. Clin Ther  2015,37(10),2366-2380","journal-title":"Clin Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11910-013-0394-8","volume":"13","author":"Linker R.A.","year":"2013","unstructured":"Linker R.A.; Gold R.; Dimethyl fumarate for treatment of multiple sclerosis: Mechanism of action, effectiveness, and side effects. Curr Neurol Neurosci Rep  2013,13(11),394","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1586\/17512433.2013.811826","volume":"6","author":"Stangel M.","year":"2013","unstructured":"Stangel M.; Linker R.A.; Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. Expert Rev Clin Pharmacol  2013,6(4),355-362","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1352458514549398","volume":"21","author":"Hartung H.P.","year":"2015","unstructured":"Hartung H.P.; Aktas O.; Boyko A.N.; Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Mult Scler  2015,21(1),22-34","journal-title":"Mult Scler"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2147\/TCRM.S134398","volume":"13","author":"Guarnera C.","year":"2017","unstructured":"Guarnera C.; Bramanti P.; Mazzon E.; Alemtuzumab: A review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag  2017,13,871-879","journal-title":"Ther Clin Risk Manag"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12883-016-0635-y","volume":"16","author":"Gold R.","year":"2016","unstructured":"Gold R.; Radue E.W.; Giovannoni G.; Selmaj K.; Havrdova E.; Stefoski D.; Sprenger T.; Montalban X.; Cohan S.; Umans K.; Greenberg S.J.; Ozen G.; Elkins J.; Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol  2016,16(1),117","journal-title":"BMC Neurol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"Hauser S.L.","year":"2017","unstructured":"Hauser S.L.; Bar-Or A.; Comi G.; Giovannoni G.; Hartung H.P.; Hemmer B.; Lublin F.; Montalban X.; Rammohan K.W.; Selmaj K.; Traboulsee A.; Wolinsky J.S.; Arnold D.L.; Klingelschmitt G.; Masterman D.; Fontoura P.; Belachew S.; Chin P.; Mairon N.; Garren H.; Kappos L.; Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med  2017,376(3),221-234","journal-title":"N Engl J Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"CD013247","DOI":"10.1002\/14651858.CD013247.pub2","volume":"5","author":"Lin M.","year":"2022","unstructured":"Lin M.; Zhang J.; Zhang Y.; Luo J.; Shi S.; Ocrelizumab for multiple sclerosis. Cochrane Database Syst Rev  2022,5(5),CD013247","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40263-020-00771-z","volume":"34","author":"Scott L.J.","year":"2020","unstructured":"Scott L.J.; Siponimod: A review in secondary progressive multiple sclerosis. CNS Drugs  2020,34(11),1191-1200","journal-title":"CNS Drugs"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2147\/PPA.S221882","volume":"16","author":"Sabsabi S.","year":"2022","unstructured":"Sabsabi S.; Mikhael E.; Jalkh G.; Macaron G.; Rensel M.; Clinical evaluation of siponimod for the treatment of secondary progressive multiple sclerosis: Pathophysiology, efficacy, safety, patient acceptability and adherence. Patient Prefer Adherence  2022,16,1307-1319","journal-title":"Patient Prefer Adherence"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","volume":"27","author":"Rejdak K.","year":"2019","unstructured":"Rejdak K.; Stelmasiak Z.; Grieb P.; Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord  2019,27,117-120","journal-title":"Mult Scler Relat Disord"},{"key":"ref=52","author":"Ciccone I.","year":"2023","unstructured":"Ciccone I.; FDA action update, august 2023: Approvals, clearances, and designations.  Available from:  https:\/\/go.gale.com\/ps\/i.do?p=AONEandsw=wandissn=27674258andv=2.1andit=randid=GALE%7CA776918419andsid=googleScholarandlinkaccess=fulltext2023"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"Allen T.M.","year":"2013","unstructured":"Allen T.M.; Cullis P.R.; Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev  2013,65(1),36-48","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jconrel.2016.11.025","volume":"245","author":"Wen M.M.","year":"2017","unstructured":"Wen M.M.; El-Salamouni N.S.; El-Refaie W.M.; Hazzah H.A.; Ali M.M.; Tosi G.; Farid R.M.; Blanco-Prieto M.J.; Billa N.; Hanafy A.S.; Nanotechnology-based drug delivery systems for alzheimer\u2019s disease management: Technical, industrial, and clinical challenges. J Control Release  2017,245,95-107","journal-title":"J Control Release"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/apb.2015.043","volume":"5","author":"Naseri N.","year":"2015","unstructured":"Naseri N.; Valizadeh H.; Zakeri-Milani P.; Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull  2015,5(3),305-313","journal-title":"Adv Pharm Bull"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11095-010-0141-7","volume":"27","author":"Yang H.","year":"2010","unstructured":"Yang H.; Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res  2010,27(9),1759-1771","journal-title":"Pharm Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.canlet.2012.07.006","volume":"334","author":"Feng L.","year":"2013","unstructured":"Feng L.; Mumper R.J.; A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett  2013,334(2),157-175","journal-title":"Cancer Lett"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","volume":"264","author":"Tapeinos C.","year":"2017","unstructured":"Tapeinos C.; Battaglini M.; Ciofani G.; Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release  2017,264,306-332","journal-title":"J Control Release"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"238428","DOI":"10.1155\/2013\/238428","volume":"2013","author":"Masserini M.","year":"2013","unstructured":"Masserini M.; Nanoparticles for brain drug delivery. ISRN Biochem  2013,2013,238428","journal-title":"ISRN Biochem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.1021\/acsabm.0c00953","volume":"3","author":"Zeng Y.","year":"2020","unstructured":"Zeng Y.; Li Z.; Zhu H.; Gu Z.; Zhang H.; Luo K.; Recent advances in nanomedicines for multiple sclerosis therapy. ACS Appl Bio Mater  2020,3(10),6571-6597","journal-title":"ACS Appl Bio Mater"},{"key":"ref=61","first-page":"117","author":"\u00dcner M.","year":"2015","unstructured":"\u00dcner M.;  Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers  2015,117-141","journal-title":"Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.colsurfb.2011.03.035","volume":"86","author":"Silva A.C.","year":"2011","unstructured":"Silva A.C.; Gonz\u00e1lez-Mira E.; Garc\u00eda M.L.; Egea M.A.; Fonseca J.; Silva R.; Santos D.; Souto E.B.; Ferreira D.; Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces  2011,86(1),158-165","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ejpb.2014.05.004","volume":"87","author":"Gastaldi L.","year":"2014","unstructured":"Gastaldi L.; Battaglia L.; Peira E.; Chirio D.; Muntoni E.; Solazzi I.; Gallarate M.; Dosio F.; Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art. Eur J Pharm Biopharm  2014,87(3),433-444","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-022-01708-4","volume":"22","author":"Zeng L.","year":"2023","unstructured":"Zeng L.; Gowda B.H.J.; Ahmed M.G.; Abourehab M.A.S.; Chen Z.S.; Zhang C.; Li J.; Kesharwani P.; Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol Cancer  2023,22(1),10","journal-title":"Mol Cancer"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/B978-0-323-42978-8.00004-8","author":"Mandal A.","year":"2017","unstructured":"Mandal A.; Bisht R.; Pal D.; Mitra A.K.; Diagnosis and drug delivery to the brain. Med Devices (Auckl)  2017,59-83","journal-title":"Med Devices (Auckl)"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.2174\/1389557523666230511122435","volume":"23","author":"Jain S.","year":"2023","unstructured":"Jain S.; Singh R.; Paliwal S.; Sharma S.; Targeting neuroinflammation as disease modifying approach to alzheimer\u2019s disease: Potential and challenges. Mini Rev Med Chem  2023,23(22),2097-2116","journal-title":"Mini Rev Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"495103","DOI":"10.1088\/0957-4484\/26\/49\/495103","volume":"26","author":"Neves A.R.","year":"2015","unstructured":"Neves A.R.; Queiroz J.F.; Weksler B.; Romero I.A.; Couraud P.O.; Reis S.; Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: Two new strategies of functionalization with apolipoprotein E. Nanotechnology  2015,26(49),495103","journal-title":"Nanotechnology"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jconrel.2017.01.039","volume":"249","author":"Dal Magro R.","year":"2017","unstructured":"Dal Magro R.; Ornaghi F.; Cambianica I.; Beretta S.; Re F.; Musicanti C.; Rigolio R.; Donzelli E.; Canta A.; Ballarini E.; Cavaletti G.; Gasco P.; Sancini G.; ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. J Control Release  2017,249,103-110","journal-title":"J Control Release"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/10837450.2016.1226901","volume":"22","author":"Gandomi N.","year":"2017","unstructured":"Gandomi N.; Varshochian R.; Atyabi F.; Ghahremani M.H.; Sharifzadeh M.; Amini M.; Dinarvand R.; Solid lipid nanoparticles surface modified with anti-Contactin-2 or anti-Neurofascin for brain-targeted delivery of medicines. Pharm Dev Technol  2017,22(3),426-435","journal-title":"Pharm Dev Technol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/nnm.09.67","volume":"5","author":"Bond\u00ec M.L.","year":"2010","unstructured":"Bond\u00ec M.L.; Craparo E.F.; Giammona G.; Drago F.; Brain-targeted solid lipid nanoparticles containing riluzole: Preparation, characterization and biodistribution. Nanomedicine  2010,5(1),25-32","journal-title":"Nanomedicine"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1517\/17425240902939143","volume":"6","author":"Barbu E.","year":"2009","unstructured":"Barbu E.; Moln\u00e0r E.; Tsibouklis J.; G\u00f3recki D.C.; The potential for nanoparticle-based drug delivery to the brain: Overcoming the blood-brain barrier. Expert Opin Drug Deliv  2009,6(6),553-565","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejpb.2017.04.011","volume":"115","author":"Esposito E.","year":"2017","unstructured":"Esposito E.; Cortesi R.; Drechsler M.; Fan J.; Fu B.M.; Calderan L.; Mannucci S.; Boschi F.; Nastruzzi C.; Nanoformulations for dimethyl fumarate: Physicochemical characterization and in vitro\/in vivo behavior. Eur J Pharm Biopharm  2017,115,285-296","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","volume":"12","author":"Beloqui A.","year":"2016","unstructured":"Beloqui A.; Solin\u00eds M.\u00c1.; Rodr\u00edguez-Gasc\u00f3n A.; Almeida A.J.; Pr\u00e9at V.; Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine  2016,12(1),143-161","journal-title":"Nanomedicine"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/pharmaceutics12090892","volume":"12","author":"Amis T.M.","year":"2020","unstructured":"Amis T.M.; Renukuntla J.; Bolla P.K.; Clark B.A.; Selection of cryoprotectant in lyophilization of progesterone-loaded stearic acid solid lipid nanoparticles. Pharmaceutics  2020,12(9),892","journal-title":"Pharmaceutics"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0378-5173(95)04286-5","volume":"129","author":"Bunjes H.","year":"1996","unstructured":"Bunjes H.; Westesen K.; Koch M.H.J.; Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm  1996,129(1-2),159-173","journal-title":"Int J Pharm"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejpb.2011.02.009","volume":"79","author":"Priano L.","year":"2011","unstructured":"Priano L.; Zara G.P.; El-Assawy N.; Cattaldo S.; Muntoni E.; Milano E.; Serpe L.; Musicanti C.; P\u00e9rot C.; Gasco M.R.; Miscio G.; Mauro A.; Baclofen-loaded solid lipid nanoparticles: Preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration. Eur J Pharm Biopharm  2011,79(1),135-141","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jddst.2016.06.012","volume":"37","author":"Ghasemian E.","year":"2017","unstructured":"Ghasemian E.; Vatanara A.; Navidi N.; Rouini M.R.; Brain delivery of baclofen as a hydrophilic drug by nanolipid carriers: Characteristics and pharmacokinetics evaluation. J Drug Deliv Sci Technol  2017,37,67-73","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1021\/acschemneuro.7b00519","volume":"9","author":"Kumar P.","year":"2018","unstructured":"Kumar P.; Sharma G.; Gupta V.; Kaur R.; Thakur K.; Malik R.; Kumar A.; Kaushal N.; Raza K.; Preclinical explorative assessment of dimethyl fumarate-based biocompatible nanolipoidal carriers for the management of multiple sclerosis. ACS Chem Neurosci  2018,9(5),1152-1158","journal-title":"ACS Chem Neurosci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1021\/acschemneuro.6b00428","volume":"8","author":"Kumar P.","year":"2017","unstructured":"Kumar P.; Sharma G.; Kumar R.; Malik R.; Singh B.; Katare O.P.; Raza K.; Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: Evidence from pharmacokinetic, biodistribution, and cellular uptake studies. ACS Chem Neurosci  2017,8(4),860-865","journal-title":"ACS Chem Neurosci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","volume":"45","author":"Gadhave D.G.","year":"2019","unstructured":"Gadhave D.G.; Kokare C.R.; Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: Optimization and in vivo studies. Drug Dev Ind Pharm  2019,45(5),839-851","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1021\/acschemneuro.7b00041","volume":"8","author":"Kumar P.","year":"2017","unstructured":"Kumar P.; Sharma G.; Kumar R.; Malik R.; Singh B.; Katare O.P.; Raza K.; Vitamin-derived nanolipoidal carriers for brain delivery of dimethyl fumarate: A novel approach with preclinical evidence. ACS Chem Neurosci  2017,8(6),1390-1396","journal-title":"ACS Chem Neurosci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12026-015-8719-0","volume":"63","author":"Tabansky I.","year":"2015","unstructured":"Tabansky I.; Messina M.D.; Bangeranye C.; Goldstein J.; Blitz-Shabbir K.M.; Machado S.; Jeganathan V.; Wright P.; Najjar S.; Cao Y.; Sands W.; Keskin D.B.; Stern J.N.H.; Advancing drug delivery systems for the treatment of multiple sclerosis. Immunol Res  2015,63(1-3),58-69","journal-title":"Immunol Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/nbt.2434","volume":"30","author":"Getts D.R.","year":"2012","unstructured":"Getts D.R.; Martin A.J.; Mccarthy D.P.; Terry R.L.; Hunter Z.N.; Yap W.T.; Getts M.T.; Pleiss M.; Luo X.; King N.J.C.; Shea L.D.; Miller S.D.; Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol  2012,30(12),1217-1224","journal-title":"Nat Biotechnol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"7221","DOI":"10.1016\/j.biomaterials.2012.06.049","volume":"33","author":"Lewis J.S.","year":"2012","unstructured":"Lewis J.S.; Zaveri T.D.; Crooks C.P.; Keselowsky B.G.; Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials  2012,33(29),7221-7232","journal-title":"Biomaterials"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"8320","DOI":"10.1021\/nn404613v","volume":"7","author":"Lu C.H.","year":"2013","unstructured":"Lu C.H.; Willner B.; Willner I.; DNA nanotechnology: From sensing and DNA machines to drug-delivery systems. ACS Nano  2013,7(10),8320-8332","journal-title":"ACS Nano"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1734-1140(12)70901-5","volume":"64","author":"Wilczewska A.Z.","year":"2012","unstructured":"Wilczewska A.Z.; Niemirowicz K.; Markiewicz K.H.; Car H.; Nanoparticles as drug delivery systems. Pharmacol Rep  2012,64(5),1020-1037","journal-title":"Pharmacol Rep"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biomaterials.2015.03.044","volume":"56","author":"Rittchen S.","year":"2015","unstructured":"Rittchen S.; Boyd A.; Burns A.; Park J.; Fahmy T.M.; Metcalfe S.; Williams A.; Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF). Biomaterials  2015,56,78-85","journal-title":"Biomaterials"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/glia.22605","volume":"62","author":"Fischer R.","year":"2014","unstructured":"Fischer R.; Wajant H.; Kontermann R.; Pfizenmaier K.; Maier O.; Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia  2014,62(2),272-283","journal-title":"Glia"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmed.2011.11.002","volume":"18","author":"Metcalfe S.M.","year":"2012","unstructured":"Metcalfe S.M.; Fahmy T.M.; Targeted nanotherapy for induction of therapeutic immune responses. Trends Mol Med  2012,18(2),72-80","journal-title":"Trends Mol Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neuropharm.2015.07.013","volume":"99","author":"Mohajeri M.","year":"2015","unstructured":"Mohajeri M.; Sadeghizadeh M.; Najafi F.; Javan M.; Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair. Neuropharmacology  2015,99,156-167","journal-title":"Neuropharmacology"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3109\/1061186X.2011.628396","volume":"19","author":"Movassaghian S.","year":"2011","unstructured":"Movassaghian S.; Moghimi H.R.; Shirazi F.H.; Torchilin V.P.; Dendrosome-dendriplex inside liposomes: As a gene delivery system. J Drug Target  2011,19(10),925-932","journal-title":"J Drug Target"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ajps.2018.09.005","volume":"14","author":"Niu X.","year":"2019","unstructured":"Niu X.; Chen J.; Gao J.; Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. Asian J Pharm Sci  2019,14(5),480-496","journal-title":"Asian J Pharm Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrneurol.2012.76","volume":"8","author":"Srikanth M.","year":"2012","unstructured":"Srikanth M.; Kessler J.A.; Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol  2012,8(6),307-318","journal-title":"Nat Rev Neurol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","volume":"64","author":"Patel T.","year":"2012","unstructured":"Patel T.; Zhou J.; Piepmeier J.M.; Saltzman W.M.; Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev  2012,64(7),701-705","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/pharmaceutics11030101","volume":"11","author":"Teleanu D.M.","year":"2019","unstructured":"Teleanu D.M.; Chircov C.; Grumezescu A.M.; Teleanu R.I.; Neuronanomedicine: An up-to-date overview. Pharmaceutics  2019,11(3),101","journal-title":"Pharmaceutics"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/IJN.S61288","volume":"9","author":"Lu C.T.","year":"2014","unstructured":"Lu C.T.; Zhao Y.Z.; Wong H.L.; Cai J.; Peng L.; Tian X.Q.; Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine  2014,9,2241-2257","journal-title":"Int J Nanomedicine"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"e4111","DOI":"10.1002\/cbf.4111","volume":"42","author":"Chauhan A.","year":"2024","unstructured":"Chauhan A.; Dubey S.; Jain S.; Association between type 2 diabetes mellitus and alzheimer\u2019s disease: Common molecular mechanism and therapeutic targets. Cell Biochem Funct  2024,42(7),e4111","journal-title":"Cell Biochem Funct"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e0134722","DOI":"10.1371\/journal.pone.0134722","volume":"10","author":"Yuan Z.Y.","year":"2015","unstructured":"Yuan Z.Y.; Hu Y.L.; Gao J.Q.; Brain localization and neurotoxicity evaluation of polysorbate 80-modified chitosan nanoparticles in rats. PLoS One  2015,10(8),e0134722","journal-title":"PLoS One"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2147\/IJN.S25853","volume":"6","author":"Hu Y.L.","year":"2011","unstructured":"Hu Y.L.; Qi W.; Han F.; Shao J.Z.; Gao J.Q.; Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model. Int J Nanomedicine  2011,6,3351-3359","journal-title":"Int J Nanomedicine"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0168-3659(92)90199-2","volume":"22","author":"Kabanov A.V.","year":"1992","unstructured":"Kabanov A.V.; Batrakova E.V.; Melik-Nubarov N.S.; Fedoseev N.A.; Dorodnich T.Y.; Alakhov V.Y.; Chekhonin V.P.; Nazarova I.R.; Kabanov V.A.; A new class of drug carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain. J Control Release  1992,22(2),141-157","journal-title":"J Control Release"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/cancers10070238","volume":"10","author":"Hanafy N.A.N.","year":"2018","unstructured":"Hanafy N.A.N.; El-Kemary M.; Leporatti S.; Micelles structure development as a strategy to improve smart cancer therapy. Cancers  2018,10(7),238","journal-title":"Cancers"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-006-9132-0","volume":"24","author":"Torchilin V.P.","year":"2007","unstructured":"Torchilin V.P.; Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res  2007,24(1),1-16","journal-title":"Pharm Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/MDER.S70856","volume":"8","author":"Kanazawa T.","year":"2015","unstructured":"Kanazawa T.; Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles. Med Devices (Auckl)  2015,8,57-64","journal-title":"Med Devices (Auckl)"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejps.2015.12.031","volume":"83","author":"Biswas S.","year":"2016","unstructured":"Biswas S.; Kumari P.; Lakhani P.M.; Ghosh B.; Recent advances in polymeric micelles for anti-cancer drug delivery. Eur J Pharm Sci  2016,83,184-202","journal-title":"Eur J Pharm Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/17425247.2018.1529756","volume":"15","author":"Bodratti A.M.","year":"2018","unstructured":"Bodratti A.M.; Alexandridis P.; Amphiphilic block copolymers in drug delivery: Advances in formulation structure and performance. Expert Opin Drug Deliv  2018,15(11),1085-1104","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.2147\/IJN.S171794","volume":"13","author":"Lim C.","year":"2018","unstructured":"Lim C.; Moon J.; Sim T.; Hoang N.H.; Won W.R.; Lee E.S.; Youn Y.S.; Choi H.G.; Oh K.; Oh K.T.; Cyclic RGD-conjugated Pluronic\u00ae blending system for active, targeted drug delivery. Int J Nanomedicine  2018,13,4627-4639","journal-title":"Int J Nanomedicine"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jddst.2017.09.022","volume":"43","author":"Md S.","year":"2018","unstructured":"Md S.; Bhattmisra S.K.; Zeeshan F.; Shahzad N.; Mujtaba M.A.; Srikanth Meka V.; Radhakrishnan A.; Kesharwani P.; Baboota S.; Ali J.; Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. J Drug Deliv Sci Technol  2018,43,295-310","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","volume":"189","author":"Kozlovskaya L.","year":"2014","unstructured":"Kozlovskaya L.; Abou-Kaoud M.; Stepensky D.; Quantitative analysis of drug delivery to the brain via nasal route. J Control Release  2014,189,133-140","journal-title":"J Control Release"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijpharm.2015.05.021","volume":"490","author":"Serralheiro A.","year":"2015","unstructured":"Serralheiro A.; Alves G.; Fortuna A.; Falc\u00e3o A.; Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice. Int J Pharm  2015,490(1-2),39-46","journal-title":"Int J Pharm"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3109\/1547691X.2016.1159264","volume":"13","author":"Ghalamfarsa G.","year":"2016","unstructured":"Ghalamfarsa G.; Hojjat-Farsangi M.; Mohammadnia-Afrouzi M.; Anvari E.; Farhadi S.; Yousefi M.; Jadidi-Niaragh F.; Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis. J Immunotoxicol  2016,13(5),603-619","journal-title":"J Immunotoxicol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"9263","DOI":"10.3390\/molecules20059263","volume":"20","author":"Arseneault M.","year":"2015","unstructured":"Arseneault M.; Wafer C.; Morin J.F.; Recent advances in click chemistry applied to dendrimer synthesis. Molecules  2015,20(5),9263-9294","journal-title":"Molecules"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2217\/nnm.13.210","volume":"9","author":"Kesharwani P.","year":"2014","unstructured":"Kesharwani P.; Tekade R.K.; Jain N.K.; Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine  2014,9(15),2291-2308","journal-title":"Nanomedicine"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/polym14040712","volume":"14","author":"Habib S.","year":"2022","unstructured":"Habib S.; Singh M.; Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: A review. Polymers  2022,14(4),712","journal-title":"Polymers"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3390\/molecules23092238","volume":"23","author":"Florendo M.","year":"2018","unstructured":"Florendo M.; Figacz A.; Srinageshwar B.; Sharma A.; Swanson D.; Dunbar G.L.; Rossignol J.; Use of polyamidoamine dendrimers in brain diseases. Molecules  2018,23(9),2238","journal-title":"Molecules"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1016\/j.biomaterials.2014.03.064","volume":"35","author":"Kesharwani P.","year":"2014","unstructured":"Kesharwani P.; Tekade R.K.; Jain N.K.; Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials  2014,35(21),5539-5548","journal-title":"Biomaterials"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijpharm.2018.05.045","volume":"546","author":"Li J.","year":"2018","unstructured":"Li J.; Liang H.; Liu J.; Wang Z.; Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA\/siRNA for cancer therapy. Int J Pharm  2018,546(1-2),215-225","journal-title":"Int J Pharm"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jconrel.2018.10.006","volume":"291","author":"Santos S.D.","year":"2018","unstructured":"Santos S.D.; Xavier M.; Leite D.M.; Moreira D.A.; Cust\u00f3dio B.; Torrado M.; Castro R.; Leiro V.; Rodrigues J.; Tom\u00e1s H.; P\u00eago A.P.; PAMAM dendrimers: Blood-brain barrier transport and neuronal uptake after focal brain ischemia. J Control Release  2018,291,65-79","journal-title":"J Control Release"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1021\/acs.biomac.5b00643","volume":"16","author":"Hayder M.","year":"2015","unstructured":"Hayder M.; Varilh M.; Turrin C.O.; Saoudi A.; Caminade A.M.; Poupot R.; Liblau R.S.; Phosphorus-based dendrimer ABP treats neuroinflammation by promoting IL-10-producing CD4(+) T cells. Biomacromolecules  2015,16(11),3425-3433","journal-title":"Biomacromolecules"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/molecules23061272","volume":"23","author":"Fruchon S.","year":"2018","unstructured":"Fruchon S.; Poupot R.; The ABP dendrimer, a drug-candidate against inflammatory diseases that triggers the activation of Interleukin-10 producing immune cells. Molecules  2018,23(6),1272","journal-title":"Molecules"},{"key":"ref=120","year":"2018","unstructured":"Fucan-dendrimer based compounds and complexes Patent US20180251574, May 3  2018","journal-title":"Patent US20180251574, May 3"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/cplu.201900337","volume":"84","author":"Qiu J.","year":"2019","unstructured":"Qiu J.; Hameau A.; Shi X.; Mignani S.; Majoral J.P.; Caminade A.M.; Fluorescent phosphorus dendrimers: Towards material and biological applications. ChemPlusChem  2019,84(8),1070-1080","journal-title":"ChemPlusChem"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018330624241125060045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/242744\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018330624241125060045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T16:38:20Z","timestamp":1781973500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/242744\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672018330624241125060045","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}